CHRONOS THERAPEUTICS
Chronos Therapeutics’ drug development scheme focuses in two main areas: - Repositioning FDA approved drugs. - Screening, discovery and development of novel proprietary drug candidates. Current Targets - Diseases of Ageing: Osteoporosis, Cancer and Sarcopenia. - Neurodegenerative Diseases: Parkinson’s Disease, Alzheimer’s Disease, ALS and Orphan Synucleopathies. Chronos Therapeutics’ research is successfully advancing from pre-clinical stages of development for age-related dise... ase treatments to clinical development. Chronos' pioneering drug discovery and development platform the Chronoscreen has enabled the company to quickly gain proprietary positions in the regulation of cellular chronological lifespan. Some of the most exciting and effective therapeutic approaches of the future will utilize our understanding of the biological programming of life-span and ageing that take place in every cell of our body. Harnessing this knowledge will lead to novel treatments for age related diseases such as Alzheimer's Disease, Diabetes, Cancer and Osteoporosis.
CHRONOS THERAPEUTICS
Industry:
Biotechnology Health Care Therapeutics
Founded:
2009-01-01
Address:
Oxford, Oxfordshire, United Kingdom
Country:
United Kingdom
Website Url:
http://www.chronostherapeutics.com
Total Employee:
11+
Status:
Active
Contact:
+44 (0)1865 309 500
Email Addresses:
[email protected]
Total Funding:
8 M GBP
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default LetsEncrypt WordPress Wordpress Plugins Mobile Non Scaleable Content Nginx Sitelinks Search Box
Similar Organizations
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Ockham Biotech
Ockham Biotech is a research company which is focussed on the development of inhaled heparin for the treatment of airway diseases
Current Employees Featured
Investors List
University of Oxford
University of Oxford investment in Venture Round - Chronos Therapeutics
Vulpes Investment Management Pte Ltd
Vulpes Investment Management Pte Ltd investment in Venture Round - Chronos Therapeutics
Odey Asset Management
Odey Asset Management investment in Venture Round - Chronos Therapeutics
Official Site Inspections
http://www.chronostherapeutics.com
- Host name: pl1.jpcinet.co.uk
- IP address: 212.113.198.195
- Location: Crawley United Kingdom
- Latitude: 51.1149
- Longitude: -0.1841
- Timezone: Europe/London
- Postal: RH11
More informations about "Chronos Therapeutics"
Chronos Therapeutics - Crunchbase Company Profile
Chronos Therapeutics is a drug development company focused on the development of drugs for the treatment of age-related diseases.See details»
Chronos Therapeutics 2025 Company Profile: Valuation …
Information on acquisition, funding, cap tables, investors, and executives for Chronos Therapeutics. Use the PitchBook Platform to explore the full profile.See details»
Chronos Therapeutics - LinkedIn
Chronos Ltd was a biotech company focused on developing therapeutics in degenerative and behavioural diseases of the brain and nervous system. In April 2024 Chronos was acquired by TheraCryf plc.See details»
Chronos Therapeutics Company Profile | Management and
Chronos Therapeutics Profile and History Chronos Therapeutics Ltd is a privately held biotechnology company focused on diseases of ageing, brain and nervous system disorders. …See details»
Chronos Therapeutics Ltd. - Drug pipelines, Patents, Clinical trials ...
Explore Chronos Therapeutics Ltd. with its drug pipeline, therapeutic area, technology platform, 1 clinical trial, 2 news, and 3 literature, Technology Platform:Small ...See details»
CHRONOS THERAPEUTICS LIMITED overview - Find and update …
CHRONOS THERAPEUTICS LIMITED - Free company information from Companies House including registered office address, filing history, accounts, annual return, officers, charges, …See details»
Who's Who in Gerontology: Chronos Therapeutics
Chronos Therapeutics Summary CEO Huw Jones Area of work Company screening novel and repositioned drugs for the treatment of age-related conditions, particularly neurodegenerative …See details»
Chronos Therapeutics - EU-Startups
Chronos is a CNS specialist company with a high concentration of expertise in both degenerative and behavioural diseases of the brain and nervous system. What we do: Chronos is an Oxford …See details»
Chronos Therapeutics Limited Company Information - Funding, …
Get information on funding, investors, industries, and more for Chronos Therapeutics Limited. See Chronos Therapeutics Limited company profile and funding data.See details»
Chronos Therapeutics - Craft
Chronos Therapeutics is a biotechnology company operating a semi-virtual research and development model. It focuses on degenerative and behavioral diseases of the brain and …See details»
Proposed Acquisition of Chronos Therapeutics Ltd, Placing and ...
Proposed Acquisition of Chronos Therapeutics Ltd, Placing and Accompanying RetailSee details»
Chronos Therapeutics Ltd.:Company Profile & Technical Research ...
Chronos Therapeutics Ltd. is a company that provides Medicine, Pharmacy and Therapeutics, Addiction and more. Chronos Therapeutics Ltd. is headquartered in United Kingdom . Chronos …See details»
Clyde & Co advises on the sale of Chronos Therapeutics to Evgen …
Mar 21, 2024 Clyde & Co has advised the majority shareholders on the sale of Chronos Therapeutics Limited ("Chronos") to Evgen Pharma plc, a clinical stage drug development …See details»
Board of Directors Archives - Chronos Therapeutics
Martin Diggle MA (Oxon) Martin is a founder of Vulpes Investment Management, a Cayman Fund Manager which currently manages five funds including the Vulpes Life Sciences Fund, …See details»
CHRONOS THERAPEUTICS LIMITED - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for CHRONOS THERAPEUTICS LIMITED of MACCLESFIELD. Get the latest business insights from Dun & …See details»
Chronos Integration Update – Company Announcement - FT.com
Apr 5, 2024 Alderley Park, 2 May 2024 - TheraCryf plc (AIM: TCF), formerly Evgen Pharma plc, the clinical stage drug development company focussing on oncology and neuropsychiatry, …See details»
Chronos Therapeutics could be the validation of the biotech …
Jul 28, 2016 From its academic origins to its innovative assets, bold business strategy and the targeting of an unmet need, Chronos Therapeutics is the sort of company which embodies the …See details»
Shire takes stake in Chronos, hands over rights to three CNS …
Jul 20, 2016 This structure ensures that Shire will profit from the programs if they advance, while also giving it the option to buy the drugs back if they start to look particularly promising or …See details»
Chronos Therapeutics acquisitions bring hope for diseases of ageing
European CEO: By 2030, people aged 65 and up will account for nearly 20 percent of the world’s population. With the bulk of healthcare spending happening in old age, the potential for …See details»
Nutcracker Therapeutics CEO Dr. Igor Khandros Retires as
18 hours ago Board of directors member, Cynthia Collins, will serve as executive chair Dr. Khandros will remain on the board of Nutcracker Therapeutics EMERYVILLE, Calif.-- …See details»